1. Home
  2. SABA vs CRDF Comparison

SABA vs CRDF Comparison

Compare SABA & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SABA
  • CRDF
  • Stock Information
  • Founded
  • SABA 1988
  • CRDF 1999
  • Country
  • SABA United States
  • CRDF United States
  • Employees
  • SABA N/A
  • CRDF N/A
  • Industry
  • SABA
  • CRDF Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SABA
  • CRDF Health Care
  • Exchange
  • SABA Nasdaq
  • CRDF Nasdaq
  • Market Cap
  • SABA 254.3M
  • CRDF 233.5M
  • IPO Year
  • SABA N/A
  • CRDF N/A
  • Fundamental
  • Price
  • SABA $9.40
  • CRDF $2.57
  • Analyst Decision
  • SABA
  • CRDF Strong Buy
  • Analyst Count
  • SABA 0
  • CRDF 6
  • Target Price
  • SABA N/A
  • CRDF $11.92
  • AVG Volume (30 Days)
  • SABA 290.0K
  • CRDF 3.1M
  • Earning Date
  • SABA 01-01-0001
  • CRDF 07-29-2025
  • Dividend Yield
  • SABA 12.91%
  • CRDF N/A
  • EPS Growth
  • SABA N/A
  • CRDF N/A
  • EPS
  • SABA N/A
  • CRDF N/A
  • Revenue
  • SABA N/A
  • CRDF $545,000.00
  • Revenue This Year
  • SABA N/A
  • CRDF N/A
  • Revenue Next Year
  • SABA N/A
  • CRDF N/A
  • P/E Ratio
  • SABA N/A
  • CRDF N/A
  • Revenue Growth
  • SABA N/A
  • CRDF N/A
  • 52 Week Low
  • SABA $3.64
  • CRDF $2.01
  • 52 Week High
  • SABA $4.42
  • CRDF $5.64
  • Technical
  • Relative Strength Index (RSI)
  • SABA 59.88
  • CRDF 34.59
  • Support Level
  • SABA $9.17
  • CRDF $2.31
  • Resistance Level
  • SABA $9.37
  • CRDF $2.79
  • Average True Range (ATR)
  • SABA 0.13
  • CRDF 0.36
  • MACD
  • SABA 0.00
  • CRDF -0.20
  • Stochastic Oscillator
  • SABA 86.11
  • CRDF 11.56

About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest

Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Share on Social Networks: